Moderna, Inc. - Common Stock (MRNA)
241.46
+0.00 (0.00%)
NASDAQ · Last Trade: Nov 6th, 9:13 AM EST
News & Press Releases
Moderna (NASDAQ:MRNA) delivers strong Q3 2026 numbers, stock soars
Biotechnology company Moderna (NASDAQ:MRNA) reported Q3 2026 results topping the market’s revenue expectations, with revenue up 29.2% year on year to $1.31 b...
Via StockStory · November 6, 2026
Moderna (NASDAQ:MRNA) Q3 Earnings Beat and Raised Guidance Fuel Stock Rallychartmill.com
Via Chartmill · November 6, 2026
Moderna Reports Third Quarter 2026 Financial Results and Provides Business Updates
Reports third quarter revenue of $1.3 billion, GAAP net income of $0.2 billion and GAAP diluted EPS of $0.38Increases 2026 expected revenue growth to 15%-25%, exceeding the previous expectation of up to 10% growthImproves 2026 GAAP operating expense outlook by approximately $0.2 billion from previous estimateIncreases 2026 expected ending cash balance to $8.1-$8.3 billionHighlights positive Phase 3 data for intismeran and U.S. FDA approval of mFLUSIVA, the Company's fifth approved product globally
By Moderna, Inc. · Via ACCESS Newswire · November 6, 2026
Health Canada Authorizes Moderna's mRNA Influenza and Combination Influenza and COVID-19 Vaccines
Canada becomes the first country to authorize both Moderna's mRNA seasonal influenza vaccine, mFLUSIVA®, and combination influenza and COVID-19 vaccine, mCOFLU®
By Moderna, Inc. · Via ACCESS Newswire · November 5, 2026
S&P 500 After-Hours Movers: ABNB and SNDK Gain, AXON and SOLV Fallchartmill.com
Via Chartmill · November 5, 2026
Moderna (MRNA) Q3 earnings report preview: what to look for
Biotechnology company Moderna (NASDAQ:MRNA) will be reporting earnings this Friday before market hours. Here’s what to expect. Moderna beat analysts’ revenue...
Via StockStory · November 4, 2026
Universal Health Services, Tenet Healthcare, Moderna, Novavax, and Intuitive Surgical stocks trade up, what you need to know
What happened? A number of stocks jumped in the afternoon session after election results confirmed that Democrats reclaimed majorities in the House and Senat...
Via StockStory · November 4, 2026
Moderna Advances Investigational Bundibugyo Ebolavirus Vaccine Toward Phase 2/3 Study
WHO Technical Advisory Group recommends mRNA-1469 for inclusion in efficacy study following encouraging Phase 1 clinical results
By Moderna, Inc. · Via ACCESS Newswire · November 4, 2026
Moderna Announces Oral Presentation of mRNA-2808 Clinical Data at 2026 American Society of Hematology Annual Meeting
Initial Phase 1/2 data highlight the potential of Moderna's multiplexed mRNA approach in relapsed or refractory multiple myeloma
By Moderna, Inc. · Via ACCESS Newswire · November 4, 2026
Moderna's Cancer Vaccine Is Incredibly Promising, but This Could Be a Major Obstacle to Its Successfool.com
Even if the company's vaccine obtains approval, producing it at scale could be a big challenge.
Via The Motley Fool · November 3, 2026
Tempus AI Surges on Earnings Beat, But Can the Rally Last?marketbeat.com
Tempus AI posted Q3 revenue up 23.1% and a surprise profit, raised guidance, and saw shares surge 10%, though analysts cite cash burn and limited 2026 upside.
Via MarketBeat · November 3, 2026
Could Investing in Moderna's Stock Double Your Money?fool.com
The healthcare stock has generated massive returns this year and may still have room to rise even higher in the future.
Via The Motley Fool · November 3, 2026
If Moderna's CEO Is Right, the Stock's Rally Could Just Be Getting Startedfool.com
Stéphane Bancel has high hopes for the company's cancer vaccine, beyond just treating melanoma.
Via The Motley Fool · November 2, 2026
Stock Split Watch: Is Moderna Next?fool.com
Moderna stock has skyrocketed this year.
Via The Motley Fool · November 2, 2026
These 2 Stocks Have Skyrocketed in 2026. Here’s Why I’d Stay Awayfool.com
These biotechs’ valuations are through the roof.
Via The Motley Fool · October 29, 2026
Will Moderna Soar on Nov. 6?fool.com
Moderna shares have outperformed tech giants this year.
Via The Motley Fool · October 29, 2026
Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp Volatilityfool.com
Axsome's steady ascent has flipped the script—it now outpaces Moderna in quarterly revenue despite starting from a fraction of its size.
Via The Motley Fool · October 28, 2026
Merck and Moderna's Cancer Vaccine Worked—Who Gets Paid?marketbeat.com
Merck and Moderna's melanoma vaccine cut recurrence risk 42% in a Phase 3 trial, but results fell short of hopes, sending Moderna shares down sharply while Merck stock barely moved.
Via MarketBeat · October 27, 2026
S&P 500 Premarket Movers: Royal Caribbean, S&P Global Gain; Xylem, Sherwin-Williams Fallchartmill.com
Via Chartmill · October 27, 2026
S&P 500 Gap-Down Stocks for Oct. 26, 2026chartmill.com
Via Chartmill · October 26, 2026
S&P 500 Premarket Movers: Gainers and Losers Before the Openchartmill.com
Via Chartmill · October 26, 2026
A Personalized Cancer Therapy Delivered Positive Phase 3 Results; The Next Race Is Picking Better Targets
News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.
By Biotech Insider · Via GlobeNewswire · October 26, 2026
Immuno-Oncology Emerges as a Major Force in the Global Cancer Treatment Market
EQNX::TICKER_START (NASDAQ:GTBP),(NASDAQ:MRNA),(NASDAQ:IOVA),(NASDAQ:GMAB),(NYSE:PFE) EQNX::TICKER_END
Via FinancialNewsMedia · October 26, 2026
Moderna Melanoma Therapy Cuts Recurrence Risk 42% in Phase 3 Trialmarketbeat.com
Moderna (NASDAQ:MRNA) presented Phase 3 results for intismeran, its individualized neoantigen therapy, in combination with Merck’s pembrolizumab for patients with resected high-risk melanoma. The INTerpath-001 trial met its primary endpoint of relapse-free survival and a key secondary endpoint of di
Via MarketBeat · October 24, 2026
Most Active S&P 500 Stocks for Oct. 23, 2026chartmill.com
Via Chartmill · October 23, 2026